Navigation Links
Multiple Myeloma Therapeutics Future Discussed in In-demand MP Advisors Report Published at

London,UK (PRWEB) October 01, 2013

Targeting unmet needs in treating hematological malignances through the development of innovative drugs has witnessed considerable achievements recently. Over the past 10 years, proteasome inhibitor Velcade (Bortezomib) and the immunomodulatory drugs such as Revlimid (lenalidomide) and Thalomid (thalidomide) have become the basic treatments for multiple myeloma (MM) leading to the improvement in survival rates. Nevertheless, new treatment options for relapsed/refractory multiple myeloma (RRMM) are required to further improve survival and the quality of life of this group patients, and new drugs, such as Kyprolis (carfilzomib) or Pomalyst (pomalidomide, Imnovid), have already started to successfully fulfill this need.

The ever increasing need for innovative therapies for unmet needs/challenging diseases spurs the pace of drug development, either directly or through partnership/in-licensing. Meantime, maturing pipeline, successful launches and new drug approvals sustain the growth trajectory of the biotech companies.

In-demand research report “Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A” drawn up by MP Advisors has been recently published by Market Publishers Ltd.

Report Details:

Title: Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A
Published: September, 2013
Pages: 44
Price:    US$ 2,500.00

The report offers an insightful overview of the therapies for multiple myeloma (including newly diagnosed – NDMM and relapsed/refractory – RRMM). It sheds light on the unmet needs and limitations of the current standard of care for relapsed and refractory MM patients. It describes the competitive scenario and delivers information on the leading biotech companies, covering clinical data of drugs, milestones, and valuation; indicates commercial opportunity in pursuing this therapy area. The research study reviews the early- and late-stage drugs in the clinic, covers key mergers and acquisitions in the area, provides clinical trial details of key drugs in pipeline, and offers an au-close look at the future of the drugs in the late-stage pipeline.

Report Scope:

  •     Comprehensive disease profile, review of unmet needs and description of the current standard of care.
  •     Extensive overview of the therapies for multiple myeloma (including newly diagnosed – NDMM and relapsed/refractory – RRMM).
  •     Data on the drugs in the pipeline: NDMM & RRMM – mechanism of action (MoA) and clinical stage of development.
  •     Clinical trial details of key drugs in pipeline.
  •     Discussion of the important issues related to the therapeutic area.
  •     Information on M&A and licensing deals that have taken place over the past five years.
  •     Evaluation of in-licensing and/or M&A opportunities.
  •     Insights into the competitive environment and detailed company profiles.
  •     Future outlook.

More new research reports by the publisher can be found at MP Advisors page.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Scientists uncover multiple faces of deadly breast cancer
2. Experimental Pill for Multiple Sclerosis Shows Promise
3. Fish Oil Supplements Wont Help in Multiple Sclerosis: Study
4. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
5. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
6. Multiple thought channels may help brain avoid traffic jams
7. Study shows benefit of new maintenance therapy for multiple myeloma
8. FDA Issues Multiple Sclerosis Drug Alert
9. Pot Might Help Ease Multiple Sclerosis Symptoms
10. Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
11. Multiple sclerosis patients have lower risk of cancer: UBC-VCH research
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: ) , ... firsts,: , TwinLink™ - the first dual ...
Breaking Medicine Technology: